Skip to main content

Table 2 Univariate logistic regression analysis of clinicopathologic factors and effect of neoadjuvant chemotherapy

From: Predicting pathologic response to neoadjuvant chemotherapy in patients with locally advanced breast cancer using multiparametric MRI

Variable

Univariate analysis

OR

95% CI

P value

Patient age (years)

   

 < 50

0.450

0.116–1.751

0.249

 ≥ 50

Ref

  

Histological type

   

 Invasive

1.636

0.135–19.808

0.699

 Other

Ref

  

Histologic grade*

   

 1–2

0.156

0.018–1.339

0.090

 3

Ref

  

Clinical stage*

   

 I–II

9.667

2.145–43.563

0.003

 III

Ref

  

T stage*

   

 T1–T2

0.119

0.027–0.530

0.005

 T3–T4

Ref

  

N stage*

   

 N0

0.943

0.089–10.010

0.961

 N1–3

Ref

  

Lymph node size*

   

 ≤ 1.0 cm

0.982

0.263–3.662

0.979

 > 2.0 cm

Ref

  

NAC regimen

   

 EC

1.333

0.196–9.083

0.769

 EC-T(H)

1.333

0.220–8.099

0.755

 TEC or other

Ref

  

NAC cycle

   

 1–4

1.560

0.359–6.775

0.553

 5–8

Ref

  

CEA level*

   

 Normal

0.600

0.063–5.709

0.657

 Abnormal

Ref

  

CA125 level*

   

 Normal

1.061

0.100–11.260

0.961

 Abnormal

Ref

  

CA153 level*

   

 Normal

2.333

0.341–15.952

0.388

 Abnormal

Ref

  

Breast cancer subtype

   

 TNBC

Ref

  

 Her-2 positive

0.500

0.070–3.550

0.488

 Luminal A/B

0.545

0.121–2.449

0.429

 Ki-67 status

   

 ≤ 20%

2.600

0.495–13.668

0.259

 > 20%

Ref

  
  1. NAC neoadjuvant chemotherapy, TNBC triple-negative breast cancer, EC epirubicin plus cyclophosphamide, TH docetaxel plus Herceptin, TEC docetaxel,epirubicin plus cyclophosphamide
  2. *Data are measured at baseline. The data of patient age and tumor size are mean ± standard deviation
Back to article page

BMC Medical Imaging

ISSN: 1471-2342

Contact us